The Patent Labyrinth: Why Cheaper Meds Are Stuck in Traffic

Big Pharma’s favorite maze game? Patents. They claim innovation, yet leave generic drugs entangled in legal red tape longer than a DMV line on a Monday morning. It’s the classic bait-and-switch: promise a cure, deliver a price tag thicker than a lawyer’s billable hour.

While pharmaceutical giants wax poetic about breakthrough treatments, what they really offer is a roadmap to higher costs. Consider it a toll booth nightmare where your wallet holds its breath as if it’s being drafted by your gym contractor. With every delay, there’s another bureaucratic hurdle—and we’re all just paying the fare for the privilege.